Holen Sie sich die Stockscreener-App
5.54
1.28%
0.07
Schlusskurs vom Vortag:
$5.47
Offen:
$5.52
24-Stunden-Volumen:
17,246
Relative Volume:
0.12
Marktkapitalisierung:
$3.43M
Einnahmen:
$644.60K
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.00661
EPS:
-837.9618
Netto-Cashflow:
$-9.02M
1W Leistung:
-15.93%
1M Leistung:
-35.59%
6M Leistung:
-83.94%
1J Leistung:
-95.99%
1-Tages-Spanne:
$5.38
$5.8154
1-Wochen-Bereich:
$5.3335
$6.97
52-Wochen-Spanne:
$5.3335
$142.17
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Firmenname
Biodexa Pharmaceuticals Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
5.54 | 3.39M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-08 | Eingeleitet | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa advances FAP treatment with phase 3 trial initiation By Investing.com - Investing.com Nigeria
Breakthrough FAP Treatment Enters Phase 3: How Biodexa Could Transform $7B Cancer Prevention Market - Stock Titan
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan
Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Breakthrough Oral Diabetes Drug Enters Phase 2 Trial, Could Replace Daily Insulin Injections for Millions - Stock Titan
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Biodexa shareholders approve all resolutions at general meeting - Investing.com
Biodexa Secures Full Shareholder Approval for Share Value Reset and Enhanced Director Authority - Stock Titan
Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan
Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa secures additional $3M for cancer drug trial - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com
Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India
Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire
Biodexa Special Resolution Falls 4% Short: Chairman Promises New Fundraising Proposals - Stock Titan
Finanzdaten der Biodexa Pharmaceuticals Plc Adr-Aktie (BDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):